Literature DB >> 25238122

Effect of lung squamous cell carcinoma tumor microenvironment on the CD105+ endothelial cell proteome.

Huiqin Zhuo1, Zhi Lyu, Jing Su, Jian He, Yihua Pei, Xiao Cheng, Nuo Zhou, Xiaoling Lu, Sufang Zhou, Yongxiang Zhao.   

Abstract

In lung cancer, antiangiogenic treatment targeting tumor endothelial cells (ECs) provides a survival advantage. To fully elucidate the behavior of ECs in a tumor microenvironment, high-purity (>98%) normal, paratumor-, and tumor-derived CD105(+) ECs were purified from lung squamous cell carcinoma by incubating cells with anti-CD105 antibody-coated magnetic beads. These cells exhibited typical EC characteristics. Totally, 1765 proteins were identified with high confidence by isobaric stable isotope tags and two-dimensional LC/MS/MS (iTRAQ-2DLC/MS/MS). In particular, 178 and 162 proteins were differentially expressed in paratumor- and tumor-derived ECs, respectively, compared to normal ECs. The up- and down-regulation trends showed good interassay correlation. Using gene ontology, they were classified into genes involved in major reprogramming of cellular metabolic processes, oxidative stress response, redox homeostasis, apoptosis, and platelet degranulation/activation. Moreover, tumor angiogenesis-initiating ECs appeared to acquire distinct properties. For example, cell migration and regulation of smooth muscle cell migration of paratumor-derived ECs were significantly faster than that of normal and tumor-derived ECs. Among them, two migration-associated proteins, neuropilin 1 and platelet-derived growth factor receptor β predominantly expressed in ECs of paratumor from 16 patients with lung squamous cell carcinoma, were identified as potential biomarkers for antiangiogenic therapy.

Entities:  

Keywords:  iTRAQ; lung squamous cell carcinoma; paratumor endothelial cells; proteomics; tumor endothelial cells

Mesh:

Substances:

Year:  2014        PMID: 25238122     DOI: 10.1021/pr5006229

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  6 in total

Review 1.  CD105: tumor diagnosis, prognostic marker and future tumor therapeutic target.

Authors:  Lan Li; Liping Zhong; Chao Tang; Lu Gan; Tong Mo; Jintong Na; Jian He; Yong Huang
Journal:  Clin Transl Oncol       Date:  2022-02-15       Impact factor: 3.340

2.  Data from a comparative proteomic analysis of tumor-derived lung-cancer CD105(+) endothelial cells.

Authors:  Hongwei Jin; Xiao Cheng; Yihua Pei; Jianguo Fu; Zhi Lyu; Huifang Peng; Qin Yao; Yu Jiang; Lianzhong Luo; Huiqin Zhuo
Journal:  Data Brief       Date:  2016-03-22

Review 3.  Mass spectrometry-assisted gel-based proteomics in cancer biomarker discovery: approaches and application.

Authors:  Rongrong Huang; Zhongsi Chen; Lei He; Nongyue He; Zhijiang Xi; Zhiyang Li; Yan Deng; Xin Zeng
Journal:  Theranostics       Date:  2017-08-18       Impact factor: 11.556

4.  Efficient targeted tumor imaging and secreted endostatin gene delivery by anti-CD105 immunoliposomes.

Authors:  Huiqin Zhuo; Baoshi Zheng; Jianming Liu; Yong Huang; Huiling Wang; Duo Zheng; Naiquan Mao; Jinyu Meng; Sufang Zhou; Liping Zhong; Yongxiang Zhao
Journal:  J Exp Clin Cancer Res       Date:  2018-03-02

5.  Effects of NRP1 on angiogenesis and vascular maturity in endothelial cells are dependent on the expression of SEMA4D.

Authors:  Zhi Lyu; Hongwei Jin; Zhijian Yan; Keyan Hu; Hongwei Jiang; Huifang Peng; Huiqin Zhuo
Journal:  Int J Mol Med       Date:  2020-08-03       Impact factor: 4.101

6.  Identification of key pathways and biomarkers in sorafenib-resistant hepatocellular carcinoma using bioinformatics analysis.

Authors:  Danping Huang; Weiqu Yuan; Hanmin Li; Shaodong Li; Zuanguang Chen; Hongzhi Yang
Journal:  Exp Ther Med       Date:  2018-07-09       Impact factor: 2.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.